Schizophrenia Care in Rural America - Innovating Strategies for Improving Adherence and Outcomes in Community Mental Health Centers

Activity Details
  • Credit Type: CME
  • Credit Amount: 1.00
  • Cost: Free
  • Release: Jul 2, 2018
  • Expires: Jul 1, 2019
  • Estimated Time to Complete:
    1 Hour(s)
  • System Requirements:
  • Average User Rating:
    ( Ratings)

 

Overview

Schizophrenia is a chronic, heterogeneous, and progressively disabling mental illness characterized by frequent relapses, persistence of symptoms, and substantial functional deficits.Despite pharmacologic advances, the treatment of schizophrenia remains a challenge and outcomes remain suboptimal.Major gaps in practice are evident at each point on the care continuum, including underuse of measurement-based approaches, inadequate treatment in the acute and maintenance phases, and poor medication adherence.Rural settings present unique challenges to management of schizophrenia as patients have limited access to mental health providers in addition to geographic and financial barriers to care. This online educational activity is designed to help mental health providers practicing in rural settings overcome barriers and achieve better outcomes for their patients with schizophrenia. Expert faculty will discuss the safety and efficacy of currently available antipsychotic agents, strategies for individualizing treatment and monitoring symptoms, and the role of long-acting injectables for promoting medication adherence. 

 

 

Faculty

Leslie Citrome Leslie Citrome, MD, MPH
Clinical Professor of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York

Rajiv Tandon Rajiv Tandon, MD
Professor of Psychiatry
University of Florida College of Medicine
Chief of Psychiatry
Malcom Randall Veterans Affairs Medical Center
Chief of Service
University of Florida Health
Gainesville, Florida

Target Audience

This program is designed specifically for mental health professionals practicing in a rural health setting who are involved in the care of patients with schizophrenia and schizoaffective disorders.

 

Objectives

After completing this activity, participants should be better able to:

  • Apply current guideline recommendations and available data to individualize treatment for patients with schizophrenia.
  • Review the mechanisms of action, safety, and efficacy of antipsychotic treatments for schizophrenia.
  • Use measurement-based strategies and tools to assess and manage patients with schizophrenia.
  • Evaluate nonpharmacologic and pharmacologic strategies for improving medication adherence in patients with schizophrenia.

 

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Talem Health. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This educational activity has been provided by Continuing Nursing Education Provider Unit, Boston University School of Medicine and jointly provided by Talem Health.

Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Contact Hours: 1.0 of which 1.0 are eligible for pharmacology credit.

 

Faculty Disclosure

Disclosure Policy: Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed. 

Faculty Disclosures:

Dr. Citrome has disclosed the following relationships: consultant for Acadia, Alkermes, Allergan, Forum, Intra-Cellular Therapeutics for Psychopharmacology; speaker for Acadia, Alkermes, Allergan, Janssen, Lundbeck, Merck, Neurocrine, Otsuka in Psychopharmacology; stockholder at Bristol-Myers Squibb, Eli Lilly, J & J, Merck, Pfizer; royalties from Wiley (Editor-in-Chief, International Journal of Clinical Practice), UpToDate (reviewer), Springer Healthcare (book).

Dr. Tandon (Co-Course Director) has no relevant financial relationships to disclose.

The faculty members plan on discussing unlabeled/investigational uses of a commercial product.

 

Planning Committee:

David C. Henderson, MD, CME Course Director, Boston University School of Medicine receives research grant support from Otsuka and Roche.

Carol A. Cahill, PCNS, Nurse Advisor, Boston Medical Center

Carmela Townsend, DNP, MS/MBA, RN, Lead Nurse Planner, Boston University School of Medicine

Kristopher Steinke, MD, Medical Director, Hill Country MHDD

Joanna Krause, MPH, Grants Manager, Boston University School of Medicine, CME

Erica Rusie, PharmD, Senior Director, Scientific Affairs, Talem Health, LLC

Kristin Della Volpe, Medical Writer, Scientific Affairs, Talem Health, LLC

Eric VanStone, Principal, Talem Health, LLC

The other members of the Planning Committee have no relevant financial relationships to disclose.

 

How To Claim Credit

To receive credit, participants must view the entire activity and complete the post-test and evaluation. Participants who receive a score of 75% or better will receive CME/CNE credit. A certificate of credit will be available for immediate download to those who successfully complete the post-test and evaluation.

 

Acknowledgement

This activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck.

This activity was developed in collaboration with the National Rural Health Association and Hill Country MHDD Centers.

 

Disclaimer

ALL PROGRAMS, ACTIVITIES, AND MATERIALS PROVIDED BY BOSTON UNIVERSITY OFFICE OF CONTINUING MEDICAL EDUCATION OR ITS ASSOCIATES ARE PROVIDED ON THE CONDITION THAT THEY BE USED SOLELY FOR EDUCATIONAL PURPOSES BY QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE CONTINUING MEDICAL EDUCATION PROGRAMS, ACTIVITIES OR MATERIALS. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.  NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.

©Talem Health, LLC 2018. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.